In cancer cells, impaired signalling pathways (PI3K/Akt and Ras/MAPK) and genetic mutations in oncogenes (c-Myc and mTOR) and tumour suppressors (TP53, RB1 and ATRX) promote Pol I transcription activity [12,14,15]. This evidence concerns the gene TP53 and cancer.